Wegovy dosing for the once-weekly injection starts at 0.25 mg and steps up every four weeks to a 2.4 mg maintenance dose, generally reached at week 17. The 1.7 mg weekly dose is also an accepted maintenance level when 2.4 mg is not tolerated, per the FDA clinical pharmacology review of the product. Tablet labeling uses a separate monthly escalation to a daily maintenance dose. The schedule itself is fixed; the pace is not. Most escalation visits turn on gastrointestinal tolerability rather than on the number on the scale.
Why it matters: Escalating on autopilot is the most common reason patients abandon therapy in the first three months.
The Short Version
- Start low: 0.25 mg once weekly for four weeks, for initiation only.
- Step every four weeks: 0.25 to 0.5 to 1 mg to 1.7 mg to 2.4 mg.
- Two maintenance levels: 2.4 mg weekly is recommended; 1.7 mg weekly is acceptable.
- Hold, don’t abandon: escalation can be delayed four weeks if a step is poorly tolerated.
- Confirm the label: strengths and presentations have changed; verify current labeling before writing protocols.
Wegovy Dosing Schedule for the Once-Weekly Injection
The injection is given subcutaneously once weekly, on the same day each week, with or without food. Sites include the abdomen, thigh, or upper arm, with rotation between injections. The day of the week can be changed as long as at least 48 hours separate consecutive doses.
| Treatment weeks | Dose once weekly | Role in the schedule |
|---|---|---|
| 1 through 4 | 0.25 mg | Initiation only; not intended for weight reduction |
| 5 through 8 | 0.5 mg | First escalation step |
| 9 through 12 | 1 mg | Mid-titration |
| 13 through 16 | 1.7 mg | Pre-maintenance, and an accepted maintenance dose |
| 17 onward | 2.4 mg | Recommended maintenance dose |
So the lowest labeled weekly dose is 0.25 mg and the recommended maintenance target in adults is 2.4 mg weekly, as summarized in the agency’s clinical pharmacology review of the product. The same escalation applies to eligible adolescents aged 12 years and older. A higher once-weekly strength has been evaluated in trials and labeling in this class continues to change, so confirm the current approved strengths in the official label rather than relying on secondary summaries.
Each prefilled pen in the US presentation delivers a single weekly dose at one fixed strength. Pens are not designed to be split, pooled, or partially dialed to create extra doses. Staff training on device handling pays off here; our notes on a Wegovy pen malfunction workflow cover what to record and report when a device fails.
Oral Semaglutide: How Daily Tablet Dosing Differs
Oral Wegovy dosing is structured in 30-day blocks rather than weekly steps. US prescribing information for the tablet describes a stepwise increase over roughly three months before reaching the daily maintenance dose, with 1.5 mg, 4 mg, and 9 mg as the sequential starting and intermediate levels and a 25 mg once-daily maintenance dose thereafter.
Two practical differences matter more than the numbers. First, absorption of oral semaglutide is sensitive to food, fluid volume, and co-administered oral medications, so adherence to the labeled administration instructions is part of the dose, not an optional extra. Second, switching between the tablet and the injection is not a simple milligram-for-milligram conversion. Any cross-formulation change should follow the label and be documented as a deliberate clinical decision. Because strengths and indications for the oral presentation are newer, check the current record in the National Library of Medicine’s label database before building a clinic protocol around it.
When to Increase the Dose and When to Hold
Escalate when the current dose has been tolerated for a full four weeks and the patient is taking it reliably. Weight change is not the trigger for moving up during titration; tolerability is. If a step causes significant nausea, vomiting, constipation, or reflux, labeling supports delaying the next increase by four weeks rather than stopping therapy outright.
Three decision points come up repeatedly in escalation visits:
- Partial tolerance: symptoms improving but still present, so hold at the current level.
- Dose reduction: 2.4 mg not tolerated, so step back to 1.7 mg weekly, with re-escalation considered later.
- Persistent intolerance: patient cannot tolerate 1.7 mg weekly, so reassess whether continuing is appropriate.
Missed doses deserve a written rule so staff answer consistently. In general, a missed weekly dose can be taken as soon as possible if the next scheduled dose is more than two days away, and skipped if it is sooner. After several consecutive missed weeks, the label addresses restarting with escalation to limit gastrointestinal symptoms. Build that language into your patient instructions and your phone-triage script, and keep it aligned with the current label rather than clinic folklore.
Patient Selection, Contraindications, and Monitoring
Eligibility, not dose, is the first question. The product is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with a BMI of 30 kg/m2 or greater, or 27 kg/m2 or greater with at least one weight-related comorbidity, and for adolescents aged 12 years and older with a BMI at or above the 95th percentile for age and sex. Labeling also includes cardiovascular risk reduction in adults with established cardiovascular disease and overweight or obesity.
The product carries a boxed warning for thyroid C-cell tumors seen in rodents and is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and in those with prior serious hypersensitivity to semaglutide. Verify this against the current label through the agency’s official drug approval database before intake forms are finalized.
Labeled warnings that shape monitoring include pancreatitis, gallbladder events, acute kidney injury from volume depletion, hypoglycemia when combined with insulin or a sulfonylurea, diabetic retinopathy complications in type 2 diabetes, heart rate increase, suicidal ideation or behavior, and pulmonary aspiration risk during general anesthesia or deep sedation. Semaglutide should not be combined with other semaglutide-containing products or other GLP-1 receptor agonists. Because of the long half-life, discontinuation is advised well in advance of a planned pregnancy; follow the labeled interval. For class-level context, see our overview of GLP-1 therapy in obesity treatment.
Perioperative and procedural flags
Ask about recent GLP-1 use before any sedation or general anesthesia, and document the last dose date. Delayed gastric emptying is the mechanism behind the aspiration warning, and anesthesia teams generally want that information in advance rather than on the day.
Maintenance, Plateaus, and the Questions Patients Ask
Does a higher dose mean more weight loss? In registration trials, mean weight reduction was greater at the 2.4 mg weekly target than at lower doses, so a dose-response relationship exists at the population level. That does not mean every patient needs the top dose. Some reach a clinically meaningful response at 1.7 mg weekly and stay there, and chasing the maximum dose through unmanageable nausea rarely helps adherence.
What about maintenance after a patient reaches a goal weight? Labeling does not define a step-down protocol, and obesity is managed as a chronic condition. Withdrawal data in this class show substantial weight regain after stopping, so a planned taper is not an evidence-backed default. Any decision to reduce or stop should be individualized and documented.
Diet questions come up at every escalation visit. The indication itself requires a reduced-calorie diet and increased physical activity, so nutrition is part of the therapy rather than an add-on. Practical counseling usually covers smaller portions, adequate protein and fluid, and limiting very fatty or greasy meals that aggravate nausea. Refer to a registered dietitian when intake is poor, when there is a history of disordered eating, or when comorbidities such as kidney disease or diabetes complicate targets. Clinics comparing programs often look at alternative options for obesity care workflows and at how tirzepatide and semaglutide products differ before standardizing a pathway.
Storage, Handling, and Procurement Notes
Store the injection refrigerated at 36°F to 46°F (2°C to 8°C) until use. Labeling permits keeping an unopened pen at 46°F to 86°F (8°C to 30°C) for up to 28 days if refrigeration is unavailable. Do not freeze, do not use a product that has been frozen, and keep pens in the carton to protect from light. Log refrigerator temperatures, record lot numbers and expiration dates at receipt, and segregate any product with a broken cold chain pending review.
On the sourcing side, Med Wholesale Supplies is a wholesale supplier of aesthetic, orthopedic and medical products to clinics, hospitals and medical professionals, operating since 2013. Presentations and labeling differ between markets, so confirm that what you receive matches the prescribing information you are working from, including the pen strength shown on the carton such as the Wegovy FlexTouch 1 mg presentation. Related inventory sits in the weight management collection, and device and technique content is grouped under injection safety.
Clinic Checklist for Escalation Visits
- Confirm current step: dose, start date, and weeks completed.
- Screen tolerability: nausea, vomiting, constipation, hydration, oral intake.
- Check red flags: severe abdominal pain, persistent vomiting, dehydration, mood change.
- Review interacting therapy: insulin, sulfonylureas, other incretin agents.
- Decide and record: escalate, hold four weeks, reduce, or reassess continuation.
- Reinforce administration: injection day, site rotation, missed-dose rule.
- Document each Wegovy dosing change with the rationale and next review date.
- Verify supply and storage: lot, expiration, temperature log, upcoming refill.
Clinics standardizing this pathway often pair the titration schedule with a written escalation script and a single owner for follow-up calls. Further reading on process design sits in clinic operations, while program-level context appears in our weight management articles and a broader piece on weight loss injections in practice.
This content is for general informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified clinician or pharmacist about your situation, and seek urgent care or call your local emergency number for severe or worsening symptoms.
